Compare XAIR & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XAIR | GNPX |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 10.8M |
| IPO Year | N/A | 2018 |
| Metric | XAIR | GNPX |
|---|---|---|
| Price | $1.35 | $2.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 293.4K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,802,000.00 | N/A |
| Revenue This Year | $261.11 | N/A |
| Revenue Next Year | $151.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $1.19 | $2.77 |
| 52 Week High | $11.56 | $63.00 |
| Indicator | XAIR | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 42.93 |
| Support Level | $1.19 | $2.77 |
| Resistance Level | $1.38 | $5.00 |
| Average True Range (ATR) | 0.11 | 0.48 |
| MACD | 0.01 | -0.27 |
| Stochastic Oscillator | 20.15 | 8.07 |
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.